1. Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD
- Author
-
Isabella C. Kelly, Mehul Dhanani, John Q. Trojanowski, Kimberly Zhou, Sonia Podvin, Steve L. Wagner, Atsushi Miyanohara, Shanshan Wang, Piyush M. Patel, Tong Zhang, Vivian Hook, Alexander M. Kleschevnikov, Phuong Nguyen, Joseph Leem, Natalia Kleschevnikov, Brian P. Head, David M. Roth, Hemal H. Patel, and Paul Savchenko
- Subjects
0301 basic medicine ,Aging ,caveolin-1 ,Transgene ,Hippocampus ,PSAPP ,QH426-470 ,Neurodegenerative ,membrane lipid raft ,Biology ,Alzheimer's Disease ,03 medical and health sciences ,Myelin ,0302 clinical medicine ,Neuroplasticity ,Acquired Cognitive Impairment ,Genetics ,medicine ,2.1 Biological and endogenous factors ,Aetiology ,Molecular Biology ,QH573-671 ,Neurodegeneration ,Neurosciences ,synaptic ultrastructure ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Synapsin ,medicine.disease ,gene therapy ,Brain Disorders ,Astrogliosis ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Neurological ,Caveolin 1 ,Molecular Medicine ,Original Article ,Dementia ,Cytology ,Alzheimer’s disease ,Neuroscience ,MLRs - Abstract
Alzheimer’s disease (AD) is the most common form of neurodegeneration and cognitive dysfunction in the elderly. Identifying molecular signals that mitigate and reverse neurodegeneration in AD may be exploited therapeutically. Transgenic AD mice (PSAPP) exhibit learning and memory deficits at 9 and 11 months, respectively, with associated decreased expression of caveolin-1 (Cav-1), a membrane/lipid raft (MLR) scaffolding protein necessary for synaptic and neuroplasticity. Neuronal-targeted gene therapy using synapsin-Cav-1 cDNA (SynCav1) was delivered to the hippocampus of PSAPP mice at 3 months using adeno-associated virus serotype 9 (AAV9). Bilateral SynCav1 gene therapy was able to preserve MLRs profile, learning and memory, hippocampal dendritic arbor, synaptic ultrastructure, and axonal myelin content in 9- and 11-month PSAPP mice, independent of reducing toxic amyloid deposits and astrogliosis. Our data indicate that SynCav1 gene therapy may be an option for AD and potentially in other forms of neurodegeneration of unknown etiology., Graphical abstract, The findings demonstrate that regardless of the etiology of the neuropathology, SynCav1 may be exploited to treat sporadic conditions or to be used in combination with already existing drugs or biologics designed to target known monogenic candidates linked to other neurodegenerative conditions (AD, ALS, MS).
- Published
- 2021
- Full Text
- View/download PDF